Clinical Trial Update: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lorlatinib in patients with advanced ALK-positive non-small cell lung cancer after progression on first-line second-generation ALK inhi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lorbrena (lorlatinib)

Snippet

Sponsor: Intergroupe Francophone de Cancerologie Thoracique | Conditions: Non Small Cell Lung Cancer Metastatic | Phase 2 | Status: COMPLETED